[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641953":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":23,"centralContacts":24,"locations":23,"responsibleParty":30,"collaborators":23,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":38,"eligibilityCriteria":39,"healthyVolunteers":34,"sex":40,"minAge":41,"maxAge":23,"enrollmentInfo":42,"targetDuration":23,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":51,"overallStatus":55,"whyStopped":23,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":23},{"fullName":5,"class":6},"University Medical Center Groningen","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Fluorescence molecular imaging during bronchoscopy with durvalumab-680LT at dose of 15 mg","EXPERIMENTAL","Patients will receive an intravenous administration of 15 mg durvalumab-680LT before the bronchoscopy procedure. The bronchoscopy will start with high-definition white light bronchoscopy, followed by fluorescence molecular bronchoscoy to observe the fluorescence signal and MDSFR-SFF spectroscopy to quantify the fluores-cence signal in vivo.",[13],"Drug: Fluorescence molecular imaging during bronchoscopy with durvalumab-680LT",{"label":15,"type":10,"description":16,"interventionNames":17},"Fluorescence molecular imaging during bronchoscopy with durvalumab-680LT at dose of 25 mg","Patients will receive an intravenous administration of 25 mg durvalumab-680LT before the bronchoscopy procedure. The bronchoscopy will start with high-definition white light bronchoscopy, followed by fluorescence molecular bronchoscoy to observe the fluorescence signal and MDSFR-SFF spectroscopy to quantify the fluores-cence signal in vivo.",[13],[19],{"type":20,"name":21,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Fluorescence molecular imaging during bronchoscopy with durvalumab-680LT",[9,15],null,[25],{"name":26,"role":27,"phone":28,"phoneExt":23,"email":29},"Frederike Bensch, MD, PhD","CONTACT","0031503610280","f.bensch@umcg.nl",{"type":31,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100641953","phase-2-in-vivo-fluorescence-molecular-bronchoscopy-of-dur-valumab-680lt-in-patients-with-unresectable-stage-iii-nsclc-after-chemoradiation-100641953",false,"NCT07653438","In-vivo Fluorescence Molecular Bronchoscopy of Dur-valumab-680LT in Patients With Unresectable Stage III NSCLC After Chemoradiation","In-vivo Fluorescence Molecular Bronchoscopy of Dur-valumab-680LT in Patients With Unresectable Stage III NSCLC After Chemoradiation - PulmoPrint","PulmoPrint","Inclusion Criteria:\n\n* Signed informed consent prior to participation in the study.\n* Age ≥ 18 years.\n* Histologically or cytologically confirmed unresectable stage III NSCLC.\n* Completion of concurrent platinum-based CRT\n* Eligibility for adjuvant durvalumab per standard of care.\n* At least one tumor lesion or involved lymph node accessible by bronchoscopy or endoscop-ic\u002Fendobronchial ultrasound, suitable for biopsy\u002FFNA and fluorescence measurement.\n* ECOG performance status 0-2.\n* Patient is considered fit to undergo a research bronchoscopy (with or without addition of endobronchial ultrasound; including propofol sedation or general anesthesia if either is indicated).\n\nExclusion Criteria:\n\n* Known history of infusion reactions to durvalumab, other anti-PD-L1 antibodies, or other monoclonal antibodies, according to the patient's medical history.\n* Contraindication for bronchoscopy or endoscopic\u002Fendobronchial ultrasound (if applicable), including severe uncorrectable coagulopathy, pre-existing severe respiratory insufficiency, or any other clinical reason as judged by the investigator.\n* Medical or psychiatric conditions compromising the patient's ability to provide informed consent, according to the treating physician.\n* Pregnancy or breastfeeding. A negative pregnancy test must be available for women of childbearing potential on the day of tracer administration.\n* Use of an investigational medicinal product within 30 days prior to tracer administration.","ALL","18 Years",{"count":43,"type":44},20,"ESTIMATED","INTERVENTIONAL",[47],"PHASE2","PulmoPrint is a clinical study at UMCG that investigates why some patients with unresectable stage III lung cancer stop responding to immunotherapy after chemoradiation. To do this, a small dose of a fluorescently labeled version of the immunotherapy drug durvalumab is given via an IV drip, after which a camera bronchoscopy is performed to visualize where and how much of the drug actually reaches the tumor and lymph nodes - before the actual durvalumab treatment starts.",[50],"Stage III Non-small Cell Lung Cancer",[52,53,54],"Fluorescence molecular bronchoscopy","Durvalumab-680LT","Near-infrared fluorescence imaging","NOT_YET_RECRUITING","2026-06-11",{"date":58,"type":59},"2026-06-17","ACTUAL",{"date":61,"type":44},"2026-09-01",{"date":63,"type":44},"2031-03-01",{"name":5,"class":6}]